,8,11 Importantly, because TMEM16A expression and function are independent of disease-causing mutations in the CFTR gene, this therapeutic approach is predicted to be suitable for all patients with CF irrespective of their genotype.18 This evidence concerns the gene CFTR and cystic fibrosis.